NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Cantoni, Claudia ^a   Huergo Zapico, Leticia ^a   Parodi, Monica ^b   Pedrazzi, Marco ^a   Mingari, Maria Cristina ^a   Moretta, Alessandro ^a   Sparatore, Bianca ^a   Gonzalez, Segundo ^d   Olive, Daniel ^e   Bottino, Cristina ^a   Castriconi, Roberta ^a   Vitale, Massimo ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF OVIEDO   (Spain)

^e AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; CD274 PROTEIN, HUMAN; HLA ANTIGEN; HMGB1 PROTEIN, HUMAN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; PROGRAMMED DEATH 1 LIGAND 1;

CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL INFILTRATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NATURAL KILLER CELL; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR BIOPSY; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; CYTOTOXICITY; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM METASTASIS; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD274; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HLA ANTIGENS; HMGB1 PROTEIN; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASM METASTASIS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; TUMOR MICROENVIRONMENT;

EID: 84971572890     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/4684268     Document Type: Review

References (163)

1. H. Spits, D. Artis, M. Colonna et al., "Innate lymphoid cells-a proposal for uniform nomenclature, " Nature Reviews Immunology, vol. 13, no. 2, pp. 145-149, 2013.
2. E. Montaldo, P. Vacca, L. Moretta, and M. C. Mingari, "Development of human natural killer cells and other innate lymphoid cells, " Seminars in Immunology, vol. 26, no. 2, pp. 107-113, 2014.
3. E. Vivier, D. H. Raulet, A. Moretta et al., "Innate or adaptive immunity? The example of natural killer cells, " Science, vol. 331, no. 6013, pp. 44-49, 2011.
4. E. Montaldo, P. Vacca, C. Vitale et al., "Human innate lymphoid cells, " Immunology Letters, 2016.
5. A. Cerwenka and L. L. Lanier, "Natural killer cell memory in infection, infammation and cancer, " Nature Reviews Immunology, vol. 16, no. 2, pp. 112-123, 2016.
6. L. Moretta, C. Bottino, D. Pende, M. Vitale, M. C. Mingari, and A. Moretta, "Diferent checkpoints in human NK-cell activation, " Trends in Immunology, vol. 25, no. 12, pp. 670-676, 2004.
7. C. Fauriat, E. O. Long, H.-G. Ljunggren, and Y. T. Bryceson, "Regulation of human NK-cell cytokine and chemokine production by target cell recognition, " Blood, vol. 115, no. 11, pp. 2167-2176, 2010.
8. A. Moretta, E. Marcenaro, S. Sivori, M. D. Chiesa, M. Vitale, and L. Moretta, "Early liaisons between cells of the innate immune system in infamed peripheral tissues, " Trends in Immunology, vol. 26, no. 12, pp. 668-675, 2005.
9. F. Bellora, R. Castriconi, A. Dondero et al., "TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells, " European Journal of Immunology, vol. 44, no. 6, pp. 1814-1822, 2014.
10. F. B. Torén, R. E. Riise, J. Ousbäck et al., "Human NK cells induce neutrophil apoptosis via an NKp46-and Fas-dependent mechanism, " The Journal of Immunology, vol. 188, no. 4, pp. 1668-1674, 2012.
11. H1 priming, " Nature Immunology, vol. 5, no. 12, pp. 1260-1265, 2004.
12. F. Ghiringhelli, C. Ménard, F. Martin, and L. Zitvogel, "The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression, " Immunological Reviews, vol. 214, no. 1, pp. 229-238, 2006.
13. S. Sivori, M. Falco, M. Della Chiesa et al., "CpG and double-stranded RNA trigger human NK cells by toll-like receptors: induction of cytokine release and cytotoxicity against tumors dendritic cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 27, pp. 10116-10121, 2004.
14. S. Sivori, S. Carlomagno, S. Pesce, A. Moretta, M. Vitale, and E. Marcenaro, "TLR/NCR/KIR: which one to use and when?" Frontiers in Immunology, vol. 5, article 105, 2014.
15. M. A. Cooper, T. A. Fehniger, and M. A. Caligiuri, "The biology of human natural killer-cell subsets, " Trends in Immunology, vol. 22, no. 11, pp. 633-640, 2001.
16. N. K. Björkström, P. Riese, F. Heuts et al., "Expression patterns of NKG2A, KIR, and CD57 defne a process of CD56 dim NK-cell diferentiation uncoupled from NK-cell education, " Blood, vol. 116, no. 19, pp. 3853-3864, 2010.
17. + NK-cell subset, " Blood, vol. 116, no. 19, pp. 3865-3874, 2010.
18. L. Moretta, "Dissecting CD56dim human NK cells, " Blood, vol. 116, no. 19, pp. 3689-3691, 2010.
19. T. Pradeu, S. Jaeger, and E. Vivier, "The speed of change: towards a discontinuity theory of immunity?" Nature Reviews Immunology, vol. 13, no. 10, pp. 764-769, 2013.
20. S. Kim, K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama, "In vivo natural killer cell activities revealed by natural killer cell-defcient mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2731-2736, 2000.
21. T. Lakshmikanth, S. Burke, T. H. Ali et al., "NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo, " The Journal of Clinical Investigation, vol. 119, no. 5, pp. 1251-1263, 2009.
22. K. Imai, S. Matsuyama, S. Miyake, K. Suga, and K. Nakachi, "Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population, " The Lancet, vol. 356, no. 9244, pp. 1795-1799, 2000.
23. A. Stojanovic and A. Cerwenka, "Natural killer cells and solid tumors, " Journal of Innate Immunity, vol. 3, no. 4, pp. 355-364, 2011.
24. M. Vitale, C. Cantoni, G. Pietra, M. C. Mingari, and L. Moretta, "Effect of tumor cells and tumor microenvironment on NK-cell function, " European Journal of Immunology, vol. 44, no. 6, pp. 1582-1592, 2014.
25. R. Castriconi, A. Dondero, F. Bellora et al., "Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells, " Journal of Immunology, vol. 190, no. 10, pp. 5321-5328, 2013.
26. M. Della Chiesa, S. Carlomagno, G. Frumento et al., "The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function, " Blood, vol. 108, no. 13, pp. 4118-4125, 2006.
27. E. Schlecker, N. Fiegler, A. Arnold et al., "Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30, " Cancer Research, vol. 74, no. 13, pp. 3429-3440, 2014.
28. R. Castriconi, C. Cantoni, M. D. Chiesa et al., "Transforming growth factor α1 inhibits expression of NKP30 and NKG2d receptors: consequences for the NK-mediated killing of dendritic cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4120-4125, 2003.
29. B. Hoechst, T. Voigtlaender, L. Ormandy et al., "Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor, " Hepatology, vol. 50, no. 3, pp. 799-807, 2009.
30. M. F. Sprinzl, F. Reisinger, A. Puschnik et al., "Sorafenib perpetuates cellular anticancer Effector functions by modulating the crosstalk between macrophages and natural killer cells, " Hepatology, vol. 57, no. 6, pp. 2358-2368, 2013.
31. M. Balsamo, F. Scordamaglia, G. Pietra et al., "Melanoma-associated fbroblasts modulate NK cell phenotype and antitumor cytotoxicity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 49, pp. 20847-20852, 2009.
32. G. Pietra, C. Manzini, S. Rivara et al., "Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity, " Cancer Research, vol. 72, no. 6, pp. 1407-1415, 2012.
33. C. Pasero, G. W. Gravis, M. Guerin et al., "Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity, " Cancer Research, vol. 76, no. 8, pp. 2153-2165, 2016.
34. B. Le Maux Chansac, A. Moretta, I. Vergnon et al., "NK cells infltrating a MHC class I-defcient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK Cell-triggering receptors, " The Journal of Immunology, vol. 175, no. 9, pp. 5790-5798, 2005.
35. low noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via aferent lymph, " The Journal of Immunology, vol. 192, no. 8, pp. 3805-3815, 2014.
36. P. Carrega, B. Morandi, R. Costa et al., "Natural killer cells infltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells, " Cancer, vol. 112, no. 4, pp. 863-875, 2008.
37. S. Platonova, J. Cherfls-Vicini, D. Damotte et al., "Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma, " Cancer Research, vol. 71, no. 16, pp. 5412-5422, 2011.
38. C. S. Vetter, V. Groh, P. Tor Straten, T. Spies, E.-B. Brocker, and J. C. Becker, "Expression of stress-induced MHC class I related chain molecules on human melanoma, " Journal of Investigative Dermatology, vol. 118, no. 4, pp. 600-605, 2002.
39. G. Erdag, J. T. Schaefer, M. E. Smolkin et al., "Immuno-type and immunohistologic characteristics of tumor-infltrating immune cells are associated with clinical outcome in metastatic melanoma, " Cancer Research, vol. 72, no. 5, pp. 1070-1080, 2012.
40. + natural killer cells can infltrate lymph nodes adjacent to metastatic melanoma, " Cancer Research, vol. 74, no. 1, pp. 81-92, 2014.
41. dimKIR+CD57+ highly cytotoxic NK cells in tumour-infltrated lymph nodes of melanoma patients, " Nature Communications, vol. 5, article 5639, 2014.
42. N. Halama, M. Braun, C. Kahlert et al., "Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines, " Clinical Cancer Research, vol. 17, no. 4, pp. 678-689, 2011.
43. Y. S. Rocca, M. P. Roberti, J. M. Arriaga et al., "Altered pheno-type in peripheral blood and tumor-associated NK cells from colorectal cancer patients, " Innate Immunity, vol. 19, no. 1, pp. 76-85, 2013.
44. R. Remark, M. Alifano, I. Cremer et al., "Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: infuence of tumor origin, " Clinical Cancer Research, vol. 19, no. 15, pp. 4079-4091, 2013.
45. E. Mamessier, A. Sylvain, M.-L. Tibult et al., "Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity, " Journal of Clinical Investigation, vol. 121, no. 9, pp. 3609-3622, 2011.
46. N. F. Delahaye, S. Rusakiewicz, I. Martins et al., "Alternatively spliced NKp30 isoforms afect the prognosis of gastrointestinal stromal tumors, " Nature Medicine, vol. 17, no. 6, pp. 700-707, 2011.
47. S. Rusakiewicz, M. Semeraro, M. Sarabi et al., "Immune infl-trates are prognostic factors in localized gastrointestinal stromal tumors, " Cancer Research, vol. 73, no. 12, pp. 3499-3510, 2013.
48. J. P. Tiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, "Epithelial-mesenchymal transitions in development and disease, " Cell, vol. 139, no. 5, pp. 871-890, 2009.
49. K. Polyak and R. A. Weinberg, "Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, " Nature Reviews Cancer, vol. 9, no. 4, pp. 265-273, 2009.
50. K. Kemper, P. L. de Goeje, D. S. Peeper, and R. van Amerongen, "Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy, " Cancer Research, vol. 74, no. 21, pp. 5937-5941, 2014.
51. M. Balsamo, C. Manzini, G. Pietra et al., "Hypoxia downregu-lates the expression of activating receptors involved in NK-cell-mediated target cell killing without afecting ADCC, " European Journal of Immunology, vol. 43, no. 10, pp. 2756-2764, 2013.
52. R. Kang, Q. Zhang, H. J. Zeh III, M. T. Lotze, and D. Tang, "HMGB1 in cancer: good, bad, or both?" Clinical Cancer Research, vol. 19, no. 15, pp. 4046-4057, 2013.
53. L. Zhu, X. Li, Y. Chen, J. Fang, and Z. Ge, "High-mobility group Box 1: a novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma, " Cancer Letters, vol. 357, no. 2, pp. 527-534, 2015.
54. C. E. Meacham and S. J. Morrison, "Tumour heterogeneity and cancer cell plasticity, " Nature, vol. 501, no. 7467, pp. 328-337, 2013.
55. J. H. Tsai and J. Yang, "Epithelial-mesenchymal plasticity in carcinoma metastasis, " Genes and Development, vol. 27, no. 20, pp. 2192-2206, 2013.
56. J. P. Tiery and J. P. Sleeman, "Complex networks orchestrate epithelial-mesenchymal transitions, " Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131-142, 2006.
57. E. Pirilä, N. S. Ramamurthy, T. Sorsa, T. Salo, J. Hietanen, and P. Maisi, "Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 2-chain expression in murine infammatory bowel disease (ulcerative colitis), " Digestive Diseases and Sciences, vol. 48, no. 1, pp. 93-98, 2003.
58. G. Giannelli, C. Bergamini, E. Fransvea, C. Sgarra, and S. Antonaci, "Laminin-5 with transforming growth factor-α1 induces epithelial to mesenchymal transition in hepatocellular carcinoma, " Gastroenterology, vol. 129, no. 5, pp. 1375-1383, 2005.
59. K. Cheng, G. Xie, and J.-P. Raufman, "Matrix metalloprotein-ase-7-catalyzed release of HB-EGF mediates deoxycholyltau-rine-induced proliferation of a human colon cancer cell line, " Biochemical Pharmacology, vol. 73, no. 7, pp. 1001-1012, 2007.
60. B. De Craene and G. Berx, "Regulatory networks defning EMT during cancer initiation and progression, " Nature Reviews Cancer, vol. 13, no. 2, pp. 97-110, 2013.
61. A. Cano, M. A. Ṕerez-Moreno, I. Rodrigo et al., "The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression, " Nature Cell Biology, vol. 2, no. 2, pp. 76-83, 2000.
62. J. Comijn, G. Berx, P. Vermassen et al., "The two-handed E box binding zinc fnger protein SIP1 downregulates E-cadherin and induces invasion, " Molecular Cell, vol. 7, no. 6, pp. 1267-1278, 2001.
63. K. M. Hajra, David Y-S. Chen, and E. R. Fearon, "The SLUG zinc-fnger protein represses E-cadherin in breast cancer, " Cancer Research, vol. 62, no. 6, pp. 1613-1618, 2002.
64. V. Bolós, H. Peinado, M. A. Pérez-Moreno, M. F. Fraga, M. Esteller, and A. Cano, "The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors, " Journal of Cell Science, vol. 116, part 3, pp. 499-511, 2003.
65. J. Yang, S. A. Mani, J. L. Donaher et al., "Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis, " Cell, vol. 117, no. 7, pp. 927-939, 2004.
66. P. A. Gregory, A. G. Bert, E. L. Paterson et al., "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1, " Nature Cell Biology, vol. 10, no. 5, pp. 593-601, 2008.
67. N. R. Christofersen, A. Silahtaroglu, U. A. Ørom, S. Kauppinen, and A. H. Lund, "miR-200b mediates post-transcriptional repression of ZFHX1B, " RNA, vol. 13, no. 8, pp. 1172-1178, 2007.
68. K. S. Hoek, O. M. Eichhof, N. C. Schlegel et al., "In vivo switching of human melanoma cells between proliferative and invasive states, " Cancer Research, vol. 68, no. 3, pp. 650-656, 2008.
69. M. Sáez-Ayala, M. F. Montenegro, L. Śanchez-del-Campo et al., "Directed phenotype switching as an Effective antimelanoma strategy, " Cancer Cell, vol. 24, no. 1, pp. 105-119, 2013.
70. S. Huang, M. Hölzel, T. Knijnenburg et al., "MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling, " Cell, vol. 151, no. 5, pp. 937-950, 2012.
71. F. Z. Li, A. S. Dhillon, R. L. Anderson, G. McArthur, and P. T. Ferrao, "Phenotype switching in melanoma: implications for progression and therapy, " Frontiers in Oncology, vol. 5, article 31, 2015.
72. G. P. Dunn, L. J. Old, and R. D. Schreiber, "The three Es of cancer immunoediting, " Annual Review of Immunology, vol. 22, pp. 329-360, 2004.
73. M. J. Smyth, "NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fbrosarcoma, " International Immunology, vol. 20, no. 4, p. 631, 2008.
74. M. J. Smyth, N. Y. Crowe, and D. I. Godfrey, "NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fbrosarcoma, " International Immunology, vol. 13, no. 4, pp. 459-463, 2001.
75. M. Girardi, D. E. Oppenheim, C. R. Steele et al., "Regulation of cutaneous malignancy by T cells, " Science, vol. 294, no. 5542, pp. 605-609, 2001.
76. D. Hanahan and L. M. Coussens, "Accessories to the crime: functions of cells recruited to the tumor microenvironment, " Cancer Cell, vol. 21, no. 3, pp. 309-322, 2012.
77. C.-Y. Liu, J.-Y. Xu, X.-Y. Shi et al., "M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway, " Laboratory Investigation, vol. 93, no. 7, pp. 844-854, 2013.
78. D. Marvel and D. I. Gabrilovich, "Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected, " Journal of Clinical Investigation, vol. 125, no. 9, pp. 3356-3364, 2015.
79. K. Oguma, H. Oshima, M. Aoki et al., "Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells, " The EMBO Journal, vol. 27, no. 12, pp. 1671-1681, 2008.
80. B. Toh, X. Wang, J. Keeble et al., "Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infltrating the primary tumor, " PLoS Biology, vol. 9, no. 9, Article ID e1001162, 2011.
81. C. Kudo-Saito, H. Shirako, T. Takeuchi, and Y. Kawakami, "Cancer metastasis is accelerated through immunosuppression during snail-induced EMT of cancer cells, " Cancer Cell, vol. 15, no. 3, pp. 195-206, 2009.
82. C. Mayer, S. Darb-Esfahani, A. Meyer et al., "Neutrophil granulocytes in ovarian cancer-induction of epithelial-to-mesenchymal-transition and tumor cell migration, " Journal of Cancer, vol. 7, no. 5, pp. 546-554, 2016.
83. M. Ricciardi, M. Zanotto, G. Malpeli et al., "Epithelial-to-mesenchymal transition (EMT) induced by infammatory priming elicits mesenchymal stromal cell-like immune-mod-ulatory properties in cancer cells, " British Journal of Cancer, vol. 112, pp. 1067-1075, 2015.
84. M. Kmieciak, K. L. Knutson, C. I. Dumur, and M. H. Manjili, "HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses, " European Journal of Immunology, vol. 37, no. 3, pp. 675-685, 2007.
85. K. L. Knutson, H. Lu, B. Stone et al., "Immunoediting of cancers may lead to epithelial to mesenchymal transition, " Journal of Immunology, vol. 177, no. 3, pp. 1526-1533, 2006.
86. A. López-Soto, L. Huergo-Zapico, J. A. Galvan et al., "Epithe-lial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor, " Journal of Immunology, vol. 190, no. 8, pp. 4408-4419, 2013.
87. L. Huergo-Zapico, A. Acebes-Huerta, A. López-Soto, M. Villa-Álvarez, A. P. Gonzalez-Rodriguez, and S. Gonzalez, "Molecular bases for the regulation of NKG2D ligands in cancer, " Frontiers in Immunology, vol. 5, article 106, 2014.
88. X.-H. Chen, Z.-C. Liu, G. Zhang et al., "TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells, " Molecular Immunology, vol. 65, no. 1, pp. 34-42, 2015.
89. M. Balsamo, W. Vermi, M. Parodi et al., "Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infltration in the tumor, " European Journal of Immunology, vol. 42, no. 7, pp. 1833-1842, 2012.
90. J. M. Taube, R. A. Anders, G. D. Young et al., "Colocalization of infammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, " Science Translational Medicine, vol. 4, no. 127, Article ID 127ra37, 2012.
91. D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy, " Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
92. J. M. Taube, G. D. Young, T. L. McMiller et al., "Diferential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade, " Clinical Cancer Research, vol. 21, no. 17, pp. 3969-3976, 2015.
93. R. Bellucci, A. Martin, D. Bommarito et al., "Interferon-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression, " OncoImmunology, vol. 4, no. 6, Article ID e1008824, 2015.
94. L. Chen, D. L. Gibbons, S. Goswami et al., "Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression, " Nature Communications, vol. 5, article 5241, 2014.
95. N.-K. V. Cheung and M. A. Dyer, "Neuroblastoma: developmental biology, cancer genomics and immunotherapy, " Nature Reviews Cancer, vol. 13, no. 6, pp. 397-411, 2013.
96. C. Bottino, A. Dondero, F. Bellora et al., "Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches, " Frontiers in Immunology, vol. 5, article 56, 2014.
97. A. Dondero, F. Pastorino, M. Della Chiesa et al., "PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance, " OncoImmunology, vol. 5, no. 1, Article ID e1064578, 2016.
98. S. Burke, T. Lakshmikanth, F. Colucci, and E. Carbone, "New views on natural killer cell-based immunotherapy for melanoma treatment, " Trends in Immunology, vol. 31, no. 9, pp. 339-345, 2010.
99. M. H. Sandel, F. M. Speetjens, A. G. Menon et al., "Natural killer cells infltrating colorectal cancer and MHC class I expression, " Molecular Immunology, vol. 42, no. 4, pp. 541-546, 2005.
100. G. Esendagli, K. Bruderek, T. Goldmann et al., "Malignant and non-malignant lung tissue areas are diferentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer, " Lung Cancer, vol. 59, no. 1, pp. 32-40, 2008.
101. D. R. Strayer, W. A. Carter, S. D. Mayberry, E. Pequignot, and I. Brodsky, "Low natural cytotoxicity of peripheral blood mono-nuclear cells in individuals with high familial incidence of cancer, " Cancer Research, vol. 44, no. 1, pp. 370-374, 1984.
102. G. Sconocchia, R. Arriga, L. Tornillo, L. Terracciano, S. Ferrone, and G. C. Spagnoli, "Melanoma cells inhibit NK cell functions, " Cancer Research, vol. 72, no. 20, pp. 5428-5430, 2012.
103. P. A. Albertsson, P. H. Basse, M. Hokland et al., "NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity, " Trends in Immunology, vol. 24, no. 11, pp. 603-609, 2003.
104. + NK and NK-T peripheral blood lymphocytes identifed by chemokine receptor expression repertoire, " Journal of Immunology, vol. 166, no. 11, pp. 6477-6482, 2001.
105. M. Inngjerdingen, B. Damaj, and A. A. Maghazachi, "Expression and regulation of chemokine receptors in human natural killer cells, " Blood, vol. 97, no. 2, pp. 367-375, 2001.
106. G. Bernardini, A. Gismondi, and A. Santoni, "Chemokines and NK cells: regulators of development, trafcking and functions, " Immunology Letters, vol. 145, no. 1-2, pp. 39-46, 2012.
107. F. Casilli, A. Bianchini, I. Gloaguen et al., "Inhibition of interleu-kin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2, " Biochemical Pharmacology, vol. 69, no. 3, pp. 385-394, 2005.
108. M. J. Robertson, "Role of chemokines in the biology of natural killer cells, " Journal of Leukocyte Biology, vol. 71, no. 2, pp. 173-183, 2002.
109. D. L. Hodge, W. B. Schill, J. M. Wang et al., "IL-2 and IL-12 alter NK cell responsiveness to IFN-γ-inducible protein 10 by down-regulating CXCR3 expression, " Journal of Immunology, vol. 168, no. 12, pp. 6090-6098, 2002.
110. S. Parolini, A. Santoro, E. Marcenaro et al., "The role of chem-erin in the colocalization of NK and dendritic cell subsets into infamed tissues, " Blood, vol. 109, no. 9, pp. 3625-3632, 2007.
111. J. Barlic, J. M. Sechler, and P. M. Murphy, "IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1, " Blood, vol. 102, no. 10, pp. 3494-3503, 2003.
112. + NK helper cells, " The Journal of Experimental Medicine, vol. 202, no. 7, pp. 941-953, 2005.
113. M. Wendel, I. E. Galani, E. Suri-Payer, and A. Cerwenka, "Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands, " Cancer Research, vol. 68, no. 20, pp. 8437-8445, 2008.
114. F. Vianello, N. Papeta, T. Chen et al., "Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specifc T cell chemorepulsion and escape from immune control, " The Journal of Immunology, vol. 176, no. 5, pp. 2902-2914, 2006.
115. R. K. Pachynski, B. A. Zabel, H. E. Kohrt et al., "The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses, " Journal of Experimental Medicine, vol. 209, no. 8, pp. 1427-1435, 2012.
116. J. O. Tomas and A. A. Travers, "HMG1 and 2, and related 'architectural' DNA-binding proteins, " Trends in Biochemical Sciences, vol. 26, no. 3, pp. 167-174, 2001.
117. H. Lee, N. Shin, M. Song et al., "Analysis of nuclear high mobility group box 1 (HMGB1)-binding proteins in colon cancer cells: clustering with proteins involved in secretion and extranuclear function, " Journal of Proteome Research, vol. 9, no. 9, pp. 4661-4670, 2010.
118. H. S. Hreggvidsdottir, T. Ö stberg, H. Wähämaa et al., "The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote infammation, " Journal of Leukocyte Biology, vol. 86, no. 3, pp. 655-662, 2009.
119. A. Didangelos, M. Puglia, M. Iberl, C. Sanchez-Bellot, B. Ros-chitzki, and E. J. Bradbury, "High-throughput proteomics reveal alarmins as amplifers of tissue pathology and infammation afer spinal cord injury, " Scientifc Reports, vol. 6, Article ID 21607, 2016.
120. J. Torburn, A. E. Frankel, and A. Torburn, "Regulation of HMGB1 release by autophagy, " Autophagy, vol. 5, no. 2, pp. 247-249, 2009.
121. M. T. Lotze, H. J. Zeh, A. Rubartelli et al., "The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity, " Immunological Reviews, vol. 220, no. 1, pp. 60-81, 2007.
122. H. Yang, P. Lundbäck, L. Ottosson et al., "Redox modifcation of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1), " Molecular Medicine, vol. 18, no. 2, pp. 250-259, 2012.
123. E. Venereau, M. Casalgrandi, M. Schiraldi et al., "Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinfammatory cytokine release, " Journal of Experimental Medicine, vol. 209, no. 9, pp. 1519-1528, 2012.
124. R. R. Kew, M. Penzo, D. M. Habiel, and K. B. Marcu, "The IKK-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1, " The Journal of Immunology, vol. 188, no. 5, pp. 2380-2386, 2012.
125. M. Schiraldi, A. Raucci, L. M. Muñoz et al., "HMGB1 promotes recruitment of infammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4, " The Journal of Experimental Medicine, vol. 209, no. 3, pp. 551-563, 2012.
126. D. Yang, Q. Chen, H. Yang, K. J. Tracey, M. Bustin, and J. J. Oppenheim, "High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin, " Journal of Leukocyte Biology, vol. 81, no. 1, pp. 59-66, 2007.
127. H. Yang, H. S. Hreggvidsdottir, K. Palmblad et al., "A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 26, pp. 11942-11947, 2010.
128. H. Kazama, J.-E. Ricci, J. M. Herndon, G. Hoppe, D. R. Green, and T. A. Ferguson, "Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein, " Immunity, vol. 29, no. 1, pp. 21-32, 2008.
129. D. Tang, R. Kang, C.-W. Cheh et al., "HMGB1 release and redox regulates autophagy and apoptosis in cancer cells, " Oncogene, vol. 29, no. 38, pp. 5299-5310, 2010.
130. T. Bonaldi, F. Talamo, P. Scafdi et al., "Monocytic cells hypera-cetylate chromatin protein HMGB1 to redirect it towards secretion, " The EMBO Journal, vol. 22, no. 20, pp. 5551-5560, 2003.
131. B. Lu, D. J. Antoine, K. Kwan et al., "JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 8, pp. 3068-3073, 2014.
132. K. Davis, S. Banerjee, A. Friggeri, C. Bell, E. Abraham, and M. Zerfaoui, "Poly(ADP-Ribosyl)ation of high mobility group box 1 (HMGB1) protein enhances inhibition of eferocytosis, " Molecular Medicine, vol. 18, no. 3, pp. 359-369, 2012.
133. X. Zhang, D. Wheeler, Y. Tang et al., "Calcium/calmodulin-dependent protein kinase(CaMK)IV mediates nucleocytoplas-mic shuttling and release of HMGB1 during lipopolysaccharide stimulation of macrophages, " The Journal of Immunology, vol. 181, no. 7, pp. 5015-5023, 2008.
134. Y. J. Oh, J. H. Youn, Y. Ji et al., "HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism, " Journal of Immunology, vol. 182, no. 9, pp. 5800-5809, 2009.
135. H. Lee, M. Park, N. Shin et al., "High mobility group box-1 is phosphorylated by protein kinase C zeta and secreted in colon cancer cells, " Biochemical and Biophysical Research Communications, vol. 424, no. 2, pp. 321-326, 2012.
136. J. Taira and Y. Higashimoto, "Evaluation of in vitro properties of predicted kinases that phosphorylate serine residues within nuclear localization signal 1 of high mobility group box 1, " Journal of Peptide Science, vol. 20, no. 8, pp. 613-617, 2014.
137. H. Wähämaa, H. Schierbeck, H. S. Hreggvidsdottir et al., "High mobility group box protein 1 in complex with lipopolysaccha-ride or IL-1 promotes an increased infammatory phenotype in synovial fbroblasts, " Arthritis Research and Terapy, vol. 13, no. 4, article R136, 2011.
138. H. S. Hreggvidsdóttir, A. M. Lundberg, A.-C. Aveberger, L. Klevenvall, U. Andersson, and H. E. Harris, "High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor, " Molecular Medicine, vol. 18, no. 2, pp. 224-230, 2012.
139. G. Li, X. Liang, and M. T. Lotze, "HMGB1: the central cytokine for all lymphoid cells, " Frontiers in Immunology, vol. 4, article 68, 2013.
140. S. Chiba, M. Baghdadi, H. Akiba et al., "Tumor-infltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1, " Nature Immunology, vol. 13, no. 9, pp. 832-842, 2012.
141. M. Pedrazzi, M. Averna, B. Sparatore et al., "Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein, " PLoS ONE, vol. 7, no. 8, Article ID e44518, 2012.
142. S. Qin, H. Wang, R. Yuan et al., "Role of HMGB1 in apoptosis-mediated sepsis lethality, " The Journal of Experimental Medicine, vol. 203, no. 7, pp. 1637-1642, 2006.
143. H. Wang, O. Bloom, M. Zhang et al., "HMG-1 as a late mediator of endotoxin lethality in mice, " Science, vol. 285, no. 5425, pp. 248-251, 1999.
144. M. Parodi, M. Pedrazzi, C. Cantoni et al., "Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment, " OncoImmunology, vol. 4, no. 12, 2015.
145. I. Ito, J. Fukazawa, and M. Yoshida, "Post-translational methy-lation of high mobility group box 1 (HMGB1) causes its cyto-plasmic localization in neutrophils, " The Journal of Biological Chemistry, vol. 282, no. 22, pp. 16336-16344, 2007.
146. M. M. Rabadi, M.-C. Kuo, T. Ghaly et al., "Interaction between uric acid and HMGB1 translocation and release from endothe-lial cells, " American Journal of Physiology-Renal Physiology, vol. 302, no. 6, pp. F730-F741, 2012.
147. K. Feghali, K. Iwasaki, K. Tanaka et al., "Human gingival fbrob-lasts release high-mobility group box-1 protein through active and passive pathways, " Oral Microbiology and Immunology, vol. 24, no. 4, pp. 292-298, 2009.
148. Y. Moriwaka, Y. Luo, H. Ohmori et al., "HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer, " Pathobiology, vol. 77, no. 1, pp. 17-23, 2010.
149. F. Berthelot, L. Fattoum, S. Casulli, J. Gozlan, V. Maréchal, and C. Elbim, "The Effect of HMGB1, a damage-associated molecular pattern molecule, on polymorphonuclear neutrophil migration depends on its concentration, " Journal of Innate Immunity, vol. 4, no. 1, pp. 41-58, 2012.
150. J. L. Guerriero, D. Ditsworth, J. M. Catanzaro et al., "DNA alky-lating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity, " The Journal of Immunology, vol. 186, no. 6, pp. 3517-3526, 2011.
151. P.-L. Liu, J.-R. Tsai, J.-J. Hwang et al., "High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness, " American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 5, pp. 530-538, 2010.
152. G.-L. Yang, L.-H. Zhang, J.-J. Bo et al., "Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer, " Journal of Surgical Oncology, vol. 106, no. 1, pp. 57-61, 2012.
153. X. Yao, G. Zhao, H. Yang, X. Hong, L. Bie, and G. Liu, "Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma, " Journal of Cancer Research and Clinical Oncology, vol. 136, no. 5, pp. 677-684, 2010.
154. C. A. Wild, S. Brandau, R. Lotf et al., "HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer, " Oral Oncology, vol. 48, no. 5, pp. 409-416, 2012.
155. C. B. Zhao, J. M. Bao, Y. J. Lu et al., "Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer, " American Journal of Cancer Research, vol. 4, no. 4, pp. 369-377, 2014.
156. L. Zhang, J. Han, H. Wu et al., "The association of HMGB1 expression with clinicopathological signifcance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review, " PLoS ONE, vol. 9, no. 10, Article ID e110626, 2014.
157. G. Bao, Q. Qiao, H. Zhao, and X. He, "Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas, " World Journal of Surgical Oncology, vol. 8, article 52, 2010.
158. Q. Li, J. Li, T. Wen et al., "Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway, " Oncotarget, vol. 5, no. 15, pp. 6387-6403, 2014.
159. W. Yan, Y. Chang, X. Liang et al., "High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases, " Hepatology, vol. 55, no. 6, pp. 1863-1875, 2012.
160. J. R. van Beijnum, P. Nowak-Sliwinska, E. van Den Boezem, P. Hautvast, W. A. Buurman, and A. W. Grifoen, "Tumor angio-genesis is enforced by autocrine regulation of high-mobility group box 1, " Oncogene, vol. 32, no. 3, pp. 363-374, 2013.
161. S. Mitola, M. Belleri, C. Urbinati et al., "Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine, " Journal of Immunology, vol. 176, no. 1, pp. 12-15, 2006.
162. S. Jost, U. Y. Moreno-Nieves, W. F. Garcia-Beltran et al., "Dys-regulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection, " Retrovirol-ogy, vol. 10, article 74, 2013.
163. A. A. Boldyrev, E. A. Bryushkova, and E. A. Vladychenskaya, "NMDA receptors in immune competent cells, " Biochemistry, vol. 77, no. 2, pp. 128-134, 2012.